
==== Front
Hepatol Commun
Hepatol Commun
HC9
Hepatology Communications
2471-254X
Lippincott Williams & Wilkins Hagerstown, MD

39225688
HEP4-24-0718
10.1097/HC9.0000000000000519
00010
3
Editorial
The mechanistic insights behind the anticancer effects of statins in liver cancer
Chen Yiling 12carrieyl@connect.hku.hk

https://orcid.org/0000-0001-5866-4705
Wong Carmen Chak-Lui 12345cclwong@hku.hk

1 Department of Pathology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China
2 State Key Laboratory of Liver Research, The University of Hong Kong, Hong Kong, China
3 Centre for Oncology and Immunology, Hong Kong Science Park, Hong Kong, China
4 Department of Clinical Oncology, Shenzhen Key Laboratory for Cancer Metastasis and Personalized Therapy, The University of Hong Kong-Shenzhen Hospital, Shenzhen, China
5 Guangdong-Hong Kong Joint Laboratory for RNA Medicine, Sun Yat-sen University, Guangzhou, China
Correspondence Carmen Chak-Lui Wong T8-010, Block T, Queen Mary Hospital, 102 Pokfulam Road, Pokfulam, Hong Kong. Email: carmencl@pathology.hku.hk, cclwong@hku.hk
9 2024
03 9 2024
8 9 e05199 7 2024
10 7 2024
Copyright © 2024 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Association for the Study of Liver Diseases.
2024
https://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc-nd/4.0/

OPEN-ACCESSTRUE
Read-alongYES
==== Body
pmcStatins are a class of drugs widely used clinically for the management of high cholesterol and the prevention of cardiovascular diseases. Currently, 7 statins are available on the market, including lovastatin, simvastatin, atorvastatin, fluvastatin, pravastatin, rosuvastatin, and pitavastatin. Statins function as the competitive inhibitors of 3-hydroxy-3-methyl-glutaryl-CoA reductase (HMGCR) by occupying enzyme binding pocket at the nanomolar levels. HMGCR is the enzyme responsible for converting HMG-CoA to mevalonate (MVA), acting as the pivotal gatekeeper in the MVA pathway, which plays a crucial role in cholesterol biosynthesis. The MVA pathway begins with the substrate acetyl-CoA and goes through a series of enzymatic reactions to generate isopentenyl pyrophosphate. Isopentenyl pyrophosphate then undergoes condensation reactions to produce various macromolecules, including cholesterol, steroid products, dolichol, and coenzyme Q10. These metabolites are essential for many critical cellular functions. The metabolic intermediates from the MVA pathway play vital roles in promoting cancer growth. Two MVA metabolites, geranylgeranyl pyrophosphate and farnesyl pyrophosphate, facilitate protein prenylation, a posttranslational modification necessary for the membrane localization and hence activating the Rho GTPases and Ras GTPases. In addition, coenzyme Q10 functions as a lipophilic antioxidant that alleviates oxidative stress. 1 Cancer cells have increased metabolic demand for MVA-derived products. Given HMGCR’s essential roles in the MVA pathway, statins might have potential as anticancer drugs.

HCC remains a global health challenge with no curative treatment. Growing evidence demonstrated the shift of HCC etiology from virus-mediated HCC to non–virus-related HCC, accompanied by liver metabolic disorders. 2 Statins, as the anticholesterol biosynthesis agents, were evaluated for their potential in preventing HCC in epidemiological studies. It has been reported that statin users have a lower risk for HCC and liver-related mortality. 3 An observational clinical study found that patients with metabolic dysfunction–associated steatotic liver disease who had cumulative statin exposure greater than 600 defined daily doses exhibited a 70% decrease in the risk of HCC development. 4 Remarkably, several population-based cohort studies consistently demonstrated the preventive effects of statins in HBV/HCV-associated HCC. 5,6 Statins were shown to be associated with a reduced hazard of liver cancer or liver-related mortality in a cohort of patients with chronic HBV and dyslipidemia. 6 Higher dosage of statins was linked to progressively lower risks of decompensation, mortality, and HCC in individuals with hepatitis virus-related cirrhosis. 7 In addition, recent reports showed that statins also reduced HCC incidence and mortality in patients with alcohol-associated liver disease. 8 Statins were also associated with decreased tumor recurrence and a more favorable prognosis in patients who received surgical treatments such as hepatectomy or liver transplantation. 9,10 In line with the above clinical studies, mechanistic studies further demonstrated the anticancer effects of statins in the context of HCC. Specifically, atorvastatin disrupted lipogenesis and reversed the metabolically dysregulated gut microbiota caused by a high-fat/high-cholesterol diet regimen in HCC. 11 Moreover, statins were shown to influence the pathogenicity of hepatitis viruses. Statins reversed HBV-induced Akt phosphorylation and inhibited cholesterol ester synthesis, large lipid droplet formation, and HCV viral secretion within the hepatocytes. 12,13 Overall, a mounting body of clinical and preclinical evidence has revealed the beneficial impact of statins in patients who are at risk of liver cancer due to various underlying etiological factors.

CAN STATINS TREAT LIVER CANCER IN ADDITION TO THEIR PREVENTIVE EFFECTS?

Recent studies have uncovered statins’ various metabolic modulatory roles, such as suppressing cholesterol and different MVA metabolites, enabling statins to synergize with other FDA-approved drugs in suppressing HCC. Classically, statins restrained the dysregulated cholesterol and improved the clinical outcomes of HCC. Liver cancer activated cholesterol biosynthesis through multiple signaling pathways such as MEK/ERK and c-Fos/LXRα, which supported cancer cell proliferation and protected liver tumors from apoptosis. 14 Statins treatment repressed MEK/ERK-mediated cholesterol production to inhibit HCC proliferation, metastasis, and TGF-β1/pERK-mediated angiogenesis. 15,16 Besides, the MVA pathway is essential for the function of the small GTPase protein Rho due to the posttranslational modification mediated by geranylgeranyl pyrophosphate. Statins restrained HCC growth by inhibiting Rho, which otherwise activated YAP/TAZ, the oncogenic effectors of the Hippo pathway. 17,18 Moreover, activation of the MVA pathway promoted the chemoresistance in HCC by inducing cholesterol accumulation. 19 Statins reversed the YAP-mediated chemoresistance in HCC and amplified the cytotoxic properties when combined with EGFR signaling inhibitor, chemotherapeutics dasatinib, and autophagic inhibitor. 20–22 Excitingly, statins elicited the most potent cytotoxicity effect when combined with tyrosine kinase inhibitors. 23 Besides, elevating cholesterol production promoted the TAZ/TEAD2-mediated PD-L1 expression in HCC tumors. The use of statins worked synergistically with immune checkpoint inhibitors such as anti-PD1 and anti-PDL1 to suppress HCC tumors. 17 In addition, statins remodeled the tumor microenvironment by reducing the IL-6 secretion to suppress the infiltration of tumor-associated macrophages and inducing CXCL6 to recruit cytotoxic natural killer T cells, thereby enhancing the efficiency of immune checkpoint inhibitor treatment. 24,25

In conclusion, statins are the key inhibitors of the MVA pathway, and they not only reduce lipid levels but also suppress the production of MVA metabolites, thereby impeding the initiation and development of HCC (Fig. 1). By targeting this central metabolic pathway, statin-based therapies can potentially disrupt multiple steps involved in HCC progression. Recent clinical studies have revealed the potential of statins in preventing HCC, prompting more translational studies to test their effectiveness as single agent or in combination with other HCC drugs in various preclinical models. In addition, further mechanistic studies are warranted to fully elucidate the complex roles of the MVA pathway in HCC pathogenesis and to explore more MVA inhibitors for HCC treatment.

FIGURE 1 The mechanisms by which statins suppress the growth of liver cancer cells through targeting the mevalonate pathway. (Figure is generated by Biorender).

FUNDING INFORMATION

This study is supported by National Natural Science Foundation of China—the Excellent Young Scientist Fund (Hong Kong and Macau) (Project#82022077), Research Grant Council Collaborative Research Fund (RGC CRF) (C7008-22G) (C5106-23G), Health and Medical Research Fund (HMRF) (10212546), Research Grant Council Research Impact Fund (RGC RIF) (R5008-22), Research Grant Council Theme Based Research Scheme (RGC TBRS) (T12-716/22-R), and Shenzhen Science and Technology Program (ZDSYS20210623091811035). This work is supported by the Centre for Oncology and Immunology under the Health@InnoHK initiative funded by the Innovation and Technology Commission, the Government of Hong Kong SAR, China. Carmen Chak-Lui Wong is the recipient of the University of Hong Kong Outstanding Research Supervisor Award.

CONFLICTS OF INTEREST

The authors have no conflicts to report.

Abbreviations: HMGCR, 3-hydroxy-3-methyl-glutaryl-CoA reductase; MVA, mevalonate.
==== Refs
REFERENCES

1 Mullen PJ Yu R Longo J Archer MC Penn LZ . The interplay between cell signalling and the mevalonate pathway in cancer. Nat Rev Cancer. 2016;16 :718–731.27562463
2 Singal AG Kanwal F Llovet JM . Global trends in hepatocellular carcinoma epidemiology: Implications for screening, prevention and therapy. Nat Rev Clin Oncol. 2023;20 :864–884.37884736
3 Vell MS Loomba R Krishnan A Wangensteen KJ Trebicka J Creasy KT . Association of statin use with risk of liver disease, hepatocellular carcinoma, and liver-related mortality. JAMA Netw Open. 2023;6 :e2320222.37358849
4 Zou B Odden MC Nguyen MH . Statin use and reduced hepatocellular carcinoma risk in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2023;21 :435–444.e436.35158055
5 Tsan YT Lee CH Ho WC Lin MH Wang JD Chen PC . Statins and the risk of hepatocellular carcinoma in patients with hepatitis C virus infection. J Clin Oncol. 2013;31 :1514–1521.23509319
6 Sinn DH Kang D Park Y Kim H Hong YS Cho J . Statin use and the risk of hepatocellular carcinoma among patients with chronic hepatitis B: An emulated target trial using longitudinal nationwide population cohort data. BMC Gastroenterol. 2023;23 :366.37880589
7 Chang FM Wang YP Lang HC Tsai CF Hou MC Lee FY . Statins decrease the risk of decompensation in hepatitis B virus- and hepatitis C virus-related cirrhosis: A population-based study. Hepatology. 2017;66 :896–907.28318053
8 Kraglund F Christensen DH Eiset AH Villadsen GE West J Jepsen P . Effects of statins and aspirin on HCC risk in alcohol-related cirrhosis: Nationwide emulated trials. Hepatol Commun. 2023;7 :e0013.36633465
9 Jeon D Cha HR Chung SW Choi J Lee D Shim JH . Association between statin use and the prognosis of hepatocellular carcinoma after resection: A nationwide cohort study. EClinicalMedicine. 2023;65 :102300.37965429
10 Kim DG Yim SH Min EK Choi MC Kim MS Joo DJ . Effect of statins on the recurrence of hepatocellular carcinoma after liver transplantation: An illusion revealed by exposure density sampling. Liver Int. 2023;43 :2017–2025.37365992
11 Zhang X Coker OO Chu ES Fu K Lau HCH Wang YX . Dietary cholesterol drives fatty liver-associated liver cancer by modulating gut microbiota and metabolites. Gut. 2021;70 :761–774.32694178
12 Ghalali A Martin-Renedo J Hogberg J Stenius U . Atorvastatin decreases HBx-induced Phospho-Akt in hepatocytes via P2X receptors. Mol Cancer Res. 2017;15 :714–722.28209758
13 Peyrou M Clement S Maier C Bourgoin L Branche E Conzelmann S . PTEN protein phosphatase activity regulates hepatitis C virus secretion through modulation of cholesterol metabolism. J Hepatol. 2013;59 :420–426.23623999
14 Bakiri L Hamacher R Grana O Guio-Carrion A Campos-Olivas R Martinez L . Liver carcinogenesis by FOS-dependent inflammation and cholesterol dysregulation. J Exp Med. 2017;214 :1387–1409.28356389
15 Chen Z Chen L Sun B Liu D He Y Qi L . LDLR inhibition promotes hepatocellular carcinoma proliferation and metastasis by elevating intracellular cholesterol synthesis through the MEK/ERK signaling pathway. Mol Metab. 2021;51 :101230.33823318
16 Deza Z Caimi GR Noelia M Coli L Ridruejo E Alvarez L . Atorvastatin shows antitumor effect in hepatocellular carcinoma development by inhibiting angiogenesis via TGF-β1/pERK signaling pathway. Mol Carcinog. 2023;62 :398–407.36575946
17 Saito Y Yin D Kubota N Wang X Filliol A Remotti H . A therapeutically targetable TAZ-TEAD2 pathway drives the growth of hepatocellular carcinoma via ANLN and KIF23. Gastroenterology. 2023;164 :1279–1292.36894036
18 Benhammou JN Qiao B Ko A Sinnett-Smith J Pisegna JR Rozengurt E . Lipophilic statins inhibit YAP coactivator transcriptional activity in HCC cells through Rho-mediated modulation of actin cytoskeleton. Am J Physiol Gastrointest Liver Physiol. 2023;325 :G239–G250.37366601
19 Montero J Morales A Llacuna L Lluis JM Terrones O Basanez G . Mitochondrial cholesterol contributes to chemotherapy resistance in hepatocellular carcinoma. Cancer Res. 2008;68 :5246–5256.18593925
20 Yang PM Liu YL Lin YC Shun CT Wu MS Chen CC . Inhibition of autophagy enhances anticancer effects of atorvastatin in digestive malignancies. Cancer Res. 2010;70 :7699–7709.20876807
21 El Sayed I Helmy MW El-Abhar HS . Inhibition of SRC/FAK cue: A novel pathway for the synergistic effect of rosuvastatin on the anti-cancer effect of dasatinib in hepatocellular carcinoma. Life Sci. 2018;213 :248–257.30292831
22 Dai XY Zhuang LH Wang DD Zhou TY Chang LL Gai RH . Nuclear translocation and activation of YAP by hypoxia contributes to the chemoresistance of SN38 in hepatocellular carcinoma cells. Oncotarget. 2016;7 :6933–6947.26771844
23 Shao WQ Zhu WW Luo MJ Fan MH Li Q Wang SH . Cholesterol suppresses GOLM1-dependent selective autophagy of RTKs in hepatocellular carcinoma. Cell Rep. 2022;39 :110712.35443161
24 Yu Z Guo J Liu Y Wang M Liu Z Gao Y . Nano delivery of simvastatin targets liver sinusoidal endothelial cells to remodel tumor microenvironment for hepatocellular carcinoma. J Nanobiotechnology. 2022;20 :9.34983554
25 Zhou TY Zhou YL Qian MJ Fang YZ Ye S Xin WX . Interleukin-6 induced by YAP in hepatocellular carcinoma cells recruits tumor-associated macrophages. J Pharmacol Sci. 2018;138 :89–95.30340922
